JP2009543798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543798A5 JP2009543798A5 JP2009519623A JP2009519623A JP2009543798A5 JP 2009543798 A5 JP2009543798 A5 JP 2009543798A5 JP 2009519623 A JP2009519623 A JP 2009519623A JP 2009519623 A JP2009519623 A JP 2009519623A JP 2009543798 A5 JP2009543798 A5 JP 2009543798A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- compounds
- inhibition
- drugs
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83049206P | 2006-07-12 | 2006-07-12 | |
| PCT/US2007/073111 WO2008008747A1 (en) | 2006-07-12 | 2007-07-10 | [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543798A JP2009543798A (ja) | 2009-12-10 |
| JP2009543798A5 true JP2009543798A5 (https=) | 2010-08-26 |
Family
ID=38617203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519623A Pending JP2009543798A (ja) | 2006-07-12 | 2007-07-10 | タンパク質キナーゼ阻害剤としての［４，５’］ビピリミジニル−６，４’−ジアミン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8026243B2 (https=) |
| EP (1) | EP2044036B1 (https=) |
| JP (1) | JP2009543798A (https=) |
| KR (1) | KR20090029832A (https=) |
| CN (1) | CN101511798B (https=) |
| AR (1) | AR061867A1 (https=) |
| AT (1) | ATE508119T1 (https=) |
| AU (1) | AU2007272646A1 (https=) |
| BR (1) | BRPI0714291A2 (https=) |
| CA (1) | CA2657381A1 (https=) |
| CL (1) | CL2007002017A1 (https=) |
| DE (1) | DE602007014374D1 (https=) |
| ES (1) | ES2367666T3 (https=) |
| MX (1) | MX2009000429A (https=) |
| PE (1) | PE20080548A1 (https=) |
| PL (1) | PL2044036T3 (https=) |
| PT (1) | PT2044036E (https=) |
| RU (1) | RU2009104340A (https=) |
| TW (1) | TW200811134A (https=) |
| UY (1) | UY30477A1 (https=) |
| WO (1) | WO2008008747A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008078091A1 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| CN101679409B (zh) | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| AR079545A1 (es) | 2009-12-21 | 2012-02-01 | Bayer Cropscience Ag | Tienilpiri(mi)dinilazol |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
| RU2627272C2 (ru) | 2011-10-06 | 2017-08-04 | Байер Интеллектчуал Проперти Гмбх | Гетероциклилпиридинилпиразолы |
| CN104039785A (zh) | 2011-10-06 | 2014-09-10 | 拜耳知识产权有限责任公司 | 作为杀真菌剂的杂环基吡(嘧)啶基吡唑 |
| JP6378171B2 (ja) | 2012-04-24 | 2018-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CA2886002C (en) * | 2012-09-27 | 2020-06-09 | Chugai Seiyaku Kabushiki Kaisha | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2887148T3 (es) | 2015-03-25 | 2021-12-21 | Nat Cancer Ct | Agente terapéutico contra el cáncer de vías biliares |
| US12414945B2 (en) | 2015-12-17 | 2025-09-16 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102613433B1 (ko) * | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| SG11202007591RA (en) | 2018-03-28 | 2020-09-29 | Eisai R&D Man Co Ltd | Therapeutic agent for hepatocellular carcinoma |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| KR102133595B1 (ko) | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR102112336B1 (ko) | 2019-08-12 | 2020-05-18 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| AU2004278413B2 (en) | 2003-09-30 | 2008-07-31 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| JP2009525978A (ja) | 2006-02-06 | 2009-07-16 | アイアールエム・リミテッド・ライアビリティ・カンパニー | プロテインキナーゼ阻害剤としての化合物および組成物 |
-
2007
- 2007-07-04 TW TW096124311A patent/TW200811134A/zh unknown
- 2007-07-10 AR ARP070103061A patent/AR061867A1/es unknown
- 2007-07-10 PL PL07812739T patent/PL2044036T3/pl unknown
- 2007-07-10 KR KR1020097002815A patent/KR20090029832A/ko not_active Withdrawn
- 2007-07-10 WO PCT/US2007/073111 patent/WO2008008747A1/en not_active Ceased
- 2007-07-10 MX MX2009000429A patent/MX2009000429A/es not_active Application Discontinuation
- 2007-07-10 CN CN2007800337140A patent/CN101511798B/zh not_active Expired - Fee Related
- 2007-07-10 BR BRPI0714291-9A2A patent/BRPI0714291A2/pt not_active Application Discontinuation
- 2007-07-10 RU RU2009104340/04A patent/RU2009104340A/ru not_active Application Discontinuation
- 2007-07-10 JP JP2009519623A patent/JP2009543798A/ja active Pending
- 2007-07-10 EP EP07812739A patent/EP2044036B1/en not_active Not-in-force
- 2007-07-10 DE DE602007014374T patent/DE602007014374D1/de active Active
- 2007-07-10 CA CA002657381A patent/CA2657381A1/en not_active Abandoned
- 2007-07-10 ES ES07812739T patent/ES2367666T3/es active Active
- 2007-07-10 AT AT07812739T patent/ATE508119T1/de active
- 2007-07-10 PE PE2007000885A patent/PE20080548A1/es not_active Application Discontinuation
- 2007-07-10 AU AU2007272646A patent/AU2007272646A1/en not_active Abandoned
- 2007-07-10 US US12/373,441 patent/US8026243B2/en not_active Expired - Fee Related
- 2007-07-10 PT PT07812739T patent/PT2044036E/pt unknown
- 2007-07-11 UY UY30477A patent/UY30477A1/es not_active Application Discontinuation
- 2007-07-11 CL CL200702017A patent/CL2007002017A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543798A5 (https=) | ||
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| JP6689841B2 (ja) | スーパーエンハンサー領域において転写制御を標的とする方法 | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| WO2012047017A3 (ko) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 | |
| DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
| MX2009004908A (es) | Compuestos quimicos. | |
| NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| WO2012173521A3 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| NZ604983A (en) | Dry powder formulation comprising an antimuscarinic drug | |
| AU2009282962A8 (en) | Compounds as kinase inhibitors | |
| Jung et al. | Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer's disease | |
| WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
| NO20074084L (no) | Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse | |
| NZ598144A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| JOP20190052A1 (ar) | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز | |
| BR112023014825A2 (pt) | Forma mórfica cristalina isolada da forma iii do composto a, forma iii do composto a, composição farmacêutica, forma de dosagem sólida, métodos para tratar coronavírus da síndrome respiratória aguda grave 2 e para tratar vírus da hepatite c, uso da forma iii do composto a ou de uma composição farmacêutica ou forma de dosagem sólida, dispersões sólidas seca por pulverização e em camadas granular, e, fabricação de forma iii do composto a |